These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29142034)

  • 1. Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study.
    Chen HL; Shen LJ; Hsu PN; Shen CY; Hall SA; Hsiao FY
    J Rheumatol; 2018 Jan; 45(1):83-89. PubMed ID: 29142034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus.
    Ruiz-Arruza I; Ugarte A; Cabezas-Rodriguez I; Medina JA; Moran MA; Ruiz-Irastorza G
    Rheumatology (Oxford); 2014 Aug; 53(8):1470-6. PubMed ID: 24681836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
    Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of incidence and clinical characteristics of osteonecrosis of femoral head in patients with systemic lupus erythematosus treated with glucocorticoid: A descriptive study based on a prospective cohort].
    Xu Y; Chen S; Cai Q; Zhang C
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2023 May; 37(5):605-614. PubMed ID: 37190840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time trend and risk factors of avascular bone necrosis in patients with systemic lupus erythematosus.
    Tse SM; Mok CC
    Lupus; 2017 Jun; 26(7):715-722. PubMed ID: 27831540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study.
    Long Y; Zhang S; Zhao J; You H; Zhang L; Li J; Leng X; Wang Q; Tian X; Li M; Zeng X
    Lupus; 2021 Aug; 30(9):1459-1468. PubMed ID: 34082592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of systemic lupus erythematosus and sleep disorders: a nationwide population-based cohort study.
    Chung WS; Lin CL; Kao CH
    Lupus; 2016 Apr; 25(4):382-8. PubMed ID: 26585071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study.
    Hsu CY; Lin YS; Su YJ; Lin HF; Lin MS; Syu YJ; Cheng TT; Yu SF; Chen JF; Chen TH
    Rheumatology (Oxford); 2017 Dec; 56(12):2212-2221. PubMed ID: 29029334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid Use in Patients With Systemic Lupus Erythematosus: Association Between Dose and Health Care Utilization and Costs.
    Chen SY; Choi CB; Li Q; Yeh WS; Lee YC; Kao AH; Liang MH
    Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1086-94. PubMed ID: 25732795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.
    Tarr T; Papp G; Nagy N; Cserép E; Zeher M
    Clin Rheumatol; 2017 Feb; 36(2):327-333. PubMed ID: 27889859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials.
    Herrinton LJ; Liu L; Goldfien R; Michaels MA; Tran TN
    J Rheumatol; 2016 Aug; 43(8):1503-9. PubMed ID: 27370880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.
    Ugarte-Gil MF; Mak A; Leong J; Dharmadhikari B; Kow NY; Reátegui-Sokolova C; Elera-Fitzcarrald C; Aranow C; Arnaud L; Askanase AD; Bae SC; Bernatsky S; Bruce IN; Buyon J; Costedoat-Chalumeau N; Dooley MA; Fortin PR; Ginzler EM; Gladman DD; Hanly J; Inanc M; Isenberg D; Jacobsen S; James JA; Jönsen A; Kalunian K; Kamen DL; Lim SS; Morand E; Mosca M; Peschken C; Pons-Estel BA; Rahman A; Ramsey-Goldman R; Reynolds J; Romero-Diaz J; Ruiz-Irastorza G; Sánchez-Guerrero J; Svenungsson E; Urowitz M; Vinet E; van Vollenhoven RF; Voskuyl A; Wallace DJ; Petri MA; Manzi S; Clarke AE; Cheung M; Farewell V; Alarcon GS
    Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34930819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study.
    Lin JA; Liao CC; Lee YJ; Wu CH; Huang WQ; Chen TL
    Ann Rheum Dis; 2014 Sep; 73(9):1646-51. PubMed ID: 23740232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased organ damage associated with deterioration in volumetric bone density and bone microarchitecture in patients with systemic lupus erythematosus on longterm glucocorticoid therapy.
    Tang XL; Zhu TY; Hung VW; Qin L; Wong CK; Kun EW; Tam LS; Li EK
    J Rheumatol; 2012 Oct; 39(10):1955-63. PubMed ID: 22896029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study.
    Ruiz-Arruza I; Lozano J; Cabezas-Rodriguez I; Medina JA; Ugarte A; Erdozain JG; Ruiz-Irastorza G
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):582-591. PubMed ID: 28704598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of end-stage renal disease in systemic lupus erythematosus patients: a nationwide population-based study.
    Yu KH; Kuo CF; Chou IJ; Chiou MJ; See LC
    Int J Rheum Dis; 2016 Nov; 19(11):1175-1182. PubMed ID: 26864331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.
    Little J; Parker B; Lunt M; Hanly JG; Urowitz MB; Clarke AE; Romero-Diaz J; Gordon C; Bae SC; Bernatsky S; Wallace DJ; Merrill JT; Buyon J; Isenberg DA; Rahman A; Ginzler EM; Petri M; Dooley MA; Fortin P; Gladman DD; Steinsson K; Ramsey-Goldman R; Khamashta MA; Aranow C; Mackay M; Alarcón GS; Manzi S; Nived O; Jönsen A; Zoma AA; van Vollenhoven RF; Ramos-Casals M; Ruiz-Irastorza G; Sam Lim S; Kalunian KC; Inanc M; Kamen DL; Peschken CA; Jacobsen S; Askanase A; Sanchez-Guerrero J; Bruce IN
    Rheumatology (Oxford); 2018 Apr; 57(4):677-687. PubMed ID: 29361147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus.
    Ruiz-Irastorza G; Ugarte A; Ruiz-Arruza I; Khamashta M
    Lupus; 2020 Sep; 29(10):1155-1167. PubMed ID: 32539657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative therapy decreases the risk of lupus nephritis in patients with systemic lupus erythematosus: A population-based retrospective cohort study.
    Chang CM; Wu PC; Chiang JH; Wei YH; Chen FP; Chen TJ; Pan TL; Yen HR; Chang HH
    J Ethnopharmacol; 2017 Jan; 196():201-212. PubMed ID: 27974236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.